New indications for radiotherapy: primary liver cancer and secondary liver oligometastases

in Belgian Journal of Medical Oncology [=BJMO] (2011), 5(1), 8-13

Surgery is considered to be the standard treatment for intrahepatic malignancies, primary <br />cancers and metastatic lesions. However, a great many patients are not eligible for surgical <br ... [more ▼]

Surgery is considered to be the standard treatment for intrahepatic malignancies, primary <br />cancers and metastatic lesions. However, a great many patients are not eligible for surgical <br />intervention. Modern stereotactic radiotherapy has the potential to be an effective alternative <br />treatment modality with low toxicity for patients with primary hepatocellular carcinoma <br />and liver oligometastases. In this paper we intend to review the current status and published <br />experiences in the field of liver irradiation. [less ▲]

Cross talk between dendritic and natural killer cells in the presence of vaccine agent against cervical cancer

in Belgian Journal of Medical Oncology [=BJMO] (2010, January 30), 4

Hematopoietic stem cell transplantation in the treatment strategy of acute leukemia

in Belgian Journal of Medical Oncology [=BJMO] (2010), 4

This review article discusses the current indications for allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid or lymphoblastic leukemia

A dosimetric study comparing breast radiotherapy planned in prone versus supine position and via conformal 3D versus IMRT techniques: protocol B-POS

in Belgian Journal of Medical Oncology [=BJMO] (2010), 4(4),

A phase I trial on LBH 589 (panobinostat), a histone deacetylase inhibitor (HDAC i) in combination with external radiotherapy for the treatment of prostate cancer, esophageal cancer and head and neck cancer.

in Belgian Journal of Medical Oncology [=BJMO] (2009), 3(3), 121

Tumor Margin after conservative breast cancer surgery for early disease: an issue or not ?

in Belgian Journal of Medical Oncology [=BJMO] (2009), 3(3), 93-100

Summary is standard of care. However, the question is Conservative breast surgery (CBS), i.e. tumorec- whether this approach is able to consolidate local tomy (TUM), has replaced more radical surgical ... [more ▼]

Summary is standard of care. However, the question is Conservative breast surgery (CBS), i.e. tumorec- whether this approach is able to consolidate local tomy (TUM), has replaced more radical surgical control irrespective of the extent of the surgical approaches such as mastectomy (MAST) and margin. No consensus exists in the literature con-quadrantectomy (QUAD). The aim of surgeons is cerning what should be considered as a minimal to avoid recurrence and still obtain a good cos-and hence a safe margin. This review will summetic result. After CBS for early disease, adjuvant marize the published data in order to try to define radiation consisting of whole breast irradiation a pragmatic treatment approach. followed by a boost dose on the surgical bed is standard of care. However, the question is whether this approach is able to consolidate local control irrespective of the extent of the surgical margin. No consensus exists in the literature concerning what should be considered as a minimal and hence a safe margin. This review will summarize the published data in order to try to define a pragmatic treatment approach. [less ▲]

Is an evidence-based approach unrealistic in NSCLC?

in Belgian Journal of Medical Oncology [=BJMO] (2008), volume 2(6), 326-333

Summary Non-small cell lung cancer (NSCLC) is a heterogeneous tumour. A wide variety of treatment options is currently available. Surgery remains the mainstay of curative treatment and an operative ... [more ▼]

Summary Non-small cell lung cancer (NSCLC) is a heterogeneous tumour. A wide variety of treatment options is currently available. Surgery remains the mainstay of curative treatment and an operative approach will be selected in function of disease stage, tumour resectability and performance status of the patient. Adjuvant chemotherapy is considered standard at least for stage II and III disease. In stage III disease, resectability should be decided in function of the cytological/histological confirmation of N2 disease. If N2-disease cannot be highlighted at work-up, the patients are submitted to surgery followed by adjuvant chemotherapy. If patients are staged pN0-pN1 after surgery, ostoperative radiotherapy should not be given. However, if pN2 is discovered at surgery, there might be a place for postoperative radiotherapy but this still needs confirmation. In case of cytological/histological confirmation of pN2 disease prior to surgery, patients should not be operated but treated with a combination of oncomitant chemoradiotherapy. This treatment algorithm will be evaluated by reviewing the published evidence issued from randomized controlled trials. [less ▲]